Latest filings (excl ownership)
15-12G
Securities registration termination
25 Oct 23
EFFECT
Notice of effectiveness
25 Oct 23
POS AM
Prospectus update (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 23
10-Q
2023 Q2
Quarterly report
18 Oct 23
25-NSE
Exchange delisting
8 Sep 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Entry into a Material Definitive Agreement
31 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Jun 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
Entry into a Material Definitive Agreement
3 Feb 23
8-K
Departure of Directors or Certain Officers
20 Jan 23
8-K
Termination of a Material Definitive Agreement
9 Jan 23
8-K
Other Events
28 Nov 22
8-K
Nabriva Therapeutics Pivoting Strategic Focus
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Other Events
4 Oct 22
8-K
Material Modifications to Rights of Security Holders
16 Sep 22
8-K
Submission of Matters to a Vote of Security Holders
17 Aug 22
8-K
Other Events
11 Aug 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
3 Aug 22
CT ORDER
Confidential treatment order
18 Jul 22
DEF 14A
Definitive proxy
11 Jul 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Jul 22
PRE 14A
Preliminary proxy
29 Jun 22
8-K
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
5 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
Latest ownership filings
3
H MICHAEL HOGAN III
10 Jul 23
3
David Maggio
10 Jul 23
4
Steven P. Gelone
31 Jan 23
4
Theodore R Schroeder
31 Jan 23
4
Steven P. Gelone
10 Jan 23
4
Theodore R Schroeder
10 Jan 23
4
Theodore R Schroeder
4 Jan 23
4
Steven P. Gelone
4 Jan 23
4
Steven P. Gelone
8 Dec 22
4
Theodore R Schroeder
8 Dec 22
4
Steven P. Gelone
2 Dec 22
4
Theodore R Schroeder
2 Dec 22
4
Steven P. Gelone
8 Nov 22
4
Theodore R Schroeder
8 Nov 22
4
Theodore R Schroeder
1 Nov 22
4
Steven P. Gelone
1 Nov 22
4
Theodore R Schroeder
11 Oct 22
4
Steven P. Gelone
11 Oct 22
4
Steven P. Gelone
4 Oct 22
4
Theodore R Schroeder
4 Oct 22
4
Theodore R Schroeder
7 Sep 22
4
Steven P. Gelone
7 Sep 22
4
Theodore R Schroeder
1 Sep 22
4
Steven P. Gelone
1 Sep 22
4
Theodore R Schroeder
15 Aug 22
4
Steven P. Gelone
15 Aug 22
4
J. Christopher Naftzger
15 Aug 22
4
Daniel Dolan
15 Aug 22
4
Christine J. Guico-Pabia
15 Aug 22
4
Steven P. Gelone
8 Aug 22
4
Theodore R Schroeder
8 Aug 22
4
DANIEL D BURGESS
4 Aug 22
4
Colin MD Broom
4 Aug 22
4
Stephen W Webster
4 Aug 22
4
MARK CORRIGAN
4 Aug 22
4
Charles A Rowland Jr
3 Aug 22
4
Carrie L. Bourdow
3 Aug 22
4
Lisa Dalton
3 Aug 22
4
Theodore R Schroeder
3 Aug 22
4
Steven P. Gelone
3 Aug 22